Vericel Corp Ord

Price Chart

Risk-Adjusted Performance

Vericel Corp Ord (VCEL) Price Performance

Vericel Corp Ord (VCEL) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $34.37, up 2.08% from the previous close.

Over the past year, VCEL has traded between a low of $29.34 and a high of $45.70. The stock has lost 16.4% over this period. It is currently 24.8% below its 52-week high.

Vericel Corp Ord has a market capitalization of $1.68B, with a price-to-earnings ratio of 162.60.

About Vericel Corp Ord

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Compare Vericel Corp Ord

Side-by-side comparison against top Healthcare peers.